Similarly, the transgelin, acting via the transgelin–actin complex and modulating the reorganisation of the actin cytoskeleton, is known to participate in the regulation of the blood flows of coronary arteries, and thus is a promising therapeutic target for the treatment of myocardial ischemia [59]. This evidence concerns the gene TAGLN and myocardial ischemia.